Tilray Brands (TLRY) Change in Receivables (2017 - 2026)
Tilray Brands (TLRY) posted Change in Receivables of $9.3 million for Q1 2026, up 365.98% on a QoQ basis from $2.0 million in Q4 2025, and up 199.24% year-over-year from $3.1 million in Q1 2025.
Tilray Brands (TLRY) Change in Receivables (2017 - 2026) Analysis & Trends
Tilray Brands' Change in Receivables history runs 10 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- Quarterly Change in Receivables rose 199.24% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $15.0 million (up 26.82% YoY) and the FY2025 annual result came in at $17.8 million, up 170.74% from the prior year.
- Change in Receivables was $9.3 million for Q1 2026 at Tilray Brands, up from $2.0 million in the prior quarter.
- Across five years, Change in Receivables topped out at $18.1 million in Q2 2025 and bottomed at -$14.4 million in Q3 2025.
- A 5-year average of $1.5 million and a median of $3.1 million in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2025 — Change in Receivables plunged 789.18% — and 2026, when it surged 199.24%.
- Tilray Brands' Change in Receivables stood at -$9.8 million in 2022, then surged by 187.31% to $8.5 million in 2023, then slipped by 21.26% to $6.7 million in 2024, then slumped by 70.25% to $2.0 million in 2025, then surged by 365.98% to $9.3 million in 2026.
- Business Quant data shows TLRY's Change in Receivables at $9.3 million in Q1 2026, $2.0 million in Q4 2025, and -$14.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | 9.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 9.30 Mn |
| Feb 28, 2026 | 9.30 Mn |
| Nov 30, 2025 | 2.00 Mn |
| Nov 30, 2025 | 2.00 Mn |
| Aug 31, 2025 | -14.41 Mn |
| Aug 31, 2025 | -14.41 Mn |
| May 31, 2025 | 18.12 Mn |
| May 31, 2025 | 18.12 Mn |
| Feb 28, 2025 | -9.37 Mn |
| Feb 28, 2025 | -9.37 Mn |
| Nov 30, 2024 | 6.71 Mn |
| Nov 30, 2024 | 6.71 Mn |
| Aug 31, 2024 | 2.34 Mn |
| Aug 31, 2024 | 2.34 Mn |
| May 31, 2024 | 12.15 Mn |
| May 31, 2024 | 12.15 Mn |
| Feb 29, 2024 | -1.05 Mn |
| Feb 29, 2024 | -1.05 Mn |
| Nov 30, 2023 | 8.52 Mn |
| Nov 30, 2023 | 8.52 Mn |